Arshad Khanani, ARVO 2022: The phase II AAVIATE™ study: suprachoroidal delivery of RGX-314 gene therapy for neovascular AMD
The clinical outcomes of the AAVIATE study (NCT04514653) is discussed in this touchOPHTHALMOLOGY interview with Prof. Arshad Khanani (Sierra Eye Associates, Reno, NV, USA). RGX-314 is being developed as a potential one-time treatment for neovascular AMD as current anti-VEGF therapies require life-long intraocular injections to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.
The presentation entitled ‘Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022.
- What are the aims and methodology of the AAVIATE study?
- What have the initial findings taught us about the efficacy, safety and tolerability of RGX-314?
- Which patients are most likely to benefit from this treatment?
Disclosures: Arshad Khanani is a consultant for Regenxbio and discloses grant/research Support from Regenxbio.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Share this Video
Related Videos In Macular Degeneration
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Rahul Khurana, AAO 2022: Loss to follow-up in patients with nAMD treated with anti-VEGF therapy in the US
Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as […]
Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 1
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a study investigating the relationship between OCTA and fluorescein angiography/indocyanine green angiography in AMD. ‘Morphological and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!